Polomar Converts $450,000 in Owed Commissions Into 10% Note Due March 2027
PMHS sits 92% above its 52-week low of $0.065 on light trading volume (0.3× avg).
Summary
Polomar signed a $450,000 promissory note to Island 40 Group covering unpaid sales commissions. The note pays 10% interest through year-end and prime plus 4% after, maturing March 31, 2027, or earlier if the specialty pharmacy subsidiary is sold.
Key Events · Financing and Capital Events · PMHS
-
Commissions Converted to $450,000 Note
Effective November 9, 2026, Polomar executed a Promissory Note and Loan Agreement with Island 40 Group, LLC for $450,000, reflecting commissions due under a Sales Director and Distribution Agreement.
-
Interest Steps Up After Year-End
The note pays 10% simple interest through December 31, 2026, then the Wall Street Journal prime rate plus 4% until paid in full.
-
Maturity Tied to Pharmacy Sale
Principal and interest are due March 31, 2027, or immediately upon closing the contemplated acquisition of Polomar Specialty Pharmacy, LLC, whichever is earlier.
-
Subsidiary Guarantees the Note
Polomar Specialty Pharmacy, LLC is a party to the note as guarantor and accepts all obligations of the company.
Analysis · PMHS · Life Sciences
Rather than pay $450,000 in sales commissions owed to Island 40 Group in cash, Polomar signed a promissory note for that amount, guaranteed by its specialty pharmacy subsidiary. The debt carries 10% simple interest through December 31, 2026, then steps up to the Wall Street Journal prime rate plus 4%, and matures March 31, 2027 — or sooner if the company closes the sale of Polomar Specialty Pharmacy. For a company that has already flagged substantial doubt about continuing as a going concern, adding a $450,000 obligation with an acceleration trigger tied to a divestiture is a real balance-sheet constraint. The waiver of setoff and counterclaim rights further removes most of the company's defenses if a dispute arises.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PMHS was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.07 to $840,000.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.